Filing Analysis
Silence Therapeutics plc reported the results of its 2026 Annual General Meeting of Shareholders held on June 16, 2026. All nine resolutions presented to shareholders, including director re-appointments and auditor ratification, were duly passed.
📋 Key Facts
- The 2026 AGM took place on June 16, 2026.
- Rhonda Hellums and James Ede-Golightly were re-appointed as directors.
- PricewaterhouseCoopers LLP was ratified as both the U.S. independent registered public accounting firm and the U.K. statutory auditors for 2026.
- Shareholders approved the 2025 U.K. statutory annual accounts and reports.
- Executive compensation and the directors' remuneration report for 2025 were approved.
Silence Therapeutics plc issued a press release on June 11, 2026, presenting follow-up and quality-of-life data from the Phase 1 SANRECO study for divesiran in patients with polycythemia vera (PV) at the EHA 2026 Annual Congress.
📋 Key Facts
- The filing relates to the Phase 1 SANRECO study evaluating divesiran, a first-in-class siRNA therapy targeting TMPRSS6.
- The study included 21 phlebotomy-dependent patients with polycythemia vera (PV).
- Data was presented at the European Hematology Association (EHA) 2026 Annual Congress on June 11, 2026.
Silence Therapeutics entered into a new At-The-Market (ATM) sales agreement with Jefferies LLC, replacing its previous 2021 agreement. The company also updated its tax status, now stating it believes it was not a Passive Foreign Investment Company (PFIC) for the 2025 taxable year, reversing a prior assessment.
🚩 Red Flags
- Potential for shareholder dilution through the new ATM facility.
- Multiple 8-K items (1.01, 1.02, 8.01) reported in a single filing.
- Uncertainty remains regarding future PFIC status, which could still lead to adverse U.S. tax consequences.
📋 Key Facts
- Entered into an Open Market Sale Agreement with Jefferies LLC on May 18, 2026.
- The new agreement replaces a prior ATM agreement dated October 15, 2021.
- Jefferies will receive a commission of up to 3.0% of gross sales proceeds.
- The ADSs will be issued under a new shelf registration statement on Form S-3 (File No. 333-295992).
- The company corrected its prior disclosure regarding PFIC status for the year ended December 31, 2025, now believing it was not a PFIC.
Silence Therapeutics plc reported its financial results for the first quarter ended March 31, 2026, and provided a general business update. The filing was signed by Iain Ross, who continues to serve as the Interim Principal Executive Officer.
🚩 Red Flags
- The company is operating under an Interim Principal Executive Officer (Iain Ross), indicating a lack of permanent top-tier management stability.
📋 Key Facts
- The company announced Q1 2026 financial results on May 7, 2026.
- The report was furnished under Item 2.02 (Results of Operations and Financial Condition).
- Iain Ross is acting as both the Interim Principal Executive Officer and Chairman of the Board.
- The company is incorporated in England and Wales and maintains its principal executive offices in London.
Silence Therapeutics plc announced its fourth quarter and full year 2025 financial results on March 5, 2026. The company also released an updated corporate presentation detailing its business updates and pipeline progress.
🚩 Red Flags
- The company is currently led by an Interim Principal Executive Officer, indicating a pending permanent leadership transition
📋 Key Facts
- Financial results cover the fourth quarter and full year ended December 31, 2025
- Updated corporate presentation was issued in March 2026
- Iain Ross is currently serving as Interim Principal Executive Officer and Chairman of the Board
- The filing includes Item 2.02 (Results of Operations) and Item 7.01 (Regulation FD Disclosure)